Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development
about
Genetic characteristics and research progress of targeted therapy in squamous cell carcinomaLung cancer chemoprevention: current status and future prospectsEpigenetics of lung cancerSynthetic lethality in lung cancer and translation to clinical therapiesNovel Application of Junction Trees to the Interpretation of Epigenetic Differences among Lung Cancer SubtypesMolecular pathways and therapeutic targets in lung cancerLung cancer transcriptomes refined with laser capture microdissection.Epigenetic clustering of lung adenocarcinomas based on DNA methylation profiles in adjacent lung tissue: Its correlation with smoking history and chronic obstructive pulmonary diseaseLoss of the Notch effector RBPJ promotes tumorigenesis.Targeting survivin in cancer: novel drug development approaches.Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancerDistinguishing Lung Adenocarcinoma from Lung Squamous Cell Carcinoma by Two Hypomethylated and Three Hypermethylated Genes: A Meta-Analysis.EYA4 is inactivated biallelically at a high frequency in sporadic lung cancer and is associated with familial lung cancer risk.The transcriptional consequences of somatic amplifications, deletions, and rearrangements in a human lung squamous cell carcinomaDNA methylation profiles at precancerous stages associated with recurrence of lung adenocarcinoma.Epigenetic therapy in lung cancer.YEATS4 is a novel oncogene amplified in non-small cell lung cancer that regulates the p53 pathway.The detection and implication of genome instability in cancerEpigenetic therapy in non-small-cell lung cancer: targeting DNA methyltransferases and histone deacetylases.Class I HDACs are mediators of smoke carcinogen-induced stabilization of DNMT1 and serve as promising targets for chemoprevention of lung cancer.A bayesian integrative model for genetical genomics with spatially informed variable selection.Breaking the crosstalk of the cellular tumorigenic network: Hypothesis for addressing resistances to targeted therapies in advanced NSCLC.Assessment of the clinical relevance of 17q25.3 copy number and three-dimensional telomere organization in non-small lung cancer patients.Identification of a subset of human non-small cell lung cancer patients with high PI3Kβ and low PTEN expression, more prevalent in squamous cell carcinoma.Oleiferoside W from the roots of Camellia oleifera C. Abel, inducing cell cycle arrest and apoptosis in A549 cells.Quantitative or qualitative transcriptional diagnostic signatures? A case study for colorectal cancer.High levels of Phosphatase and Tensin Homolog Expression Predict Favorable Prognosis in Patients with Non-small Cell Lung Cancer.
P2860
Q26865529-1C68A9D0-A0AD-4820-B91C-5A59096679C3Q26995495-A01D8171-34BD-44D1-B95F-B63F5F862589Q26996766-77A14E9D-1350-4A10-AE0F-20CD1DF00CD8Q28072904-E4033ED8-CB4F-48B9-85F4-AC5D3C0669A9Q28645621-29826C60-9AD7-46DD-A777-C094333669E4Q33688872-6DA31D3B-9367-4E96-A8CA-9C1B6146AE04Q34429985-5C206AB1-D33A-43FE-9543-E354914C871FQ34629271-6CA08347-34A4-4A65-B5F6-05287A87D741Q34924659-51E10040-8614-4AC1-94DA-8029A7955001Q34954296-9B41402C-F2D6-4F79-A681-10568B67AF6DQ35256618-68ADF2A5-0B78-40F8-B599-D6CDD8C49155Q35919451-253A3EE1-CA38-4EE2-906B-97999873F7B0Q35924241-FE5A18F4-DAE5-4E76-A445-022A65C7A75DQ36446457-7A61A89B-52A6-4799-8047-94FBC5C4BE93Q36721411-576AF5C4-8B45-48BD-9D32-C2048956CCE5Q36885903-40E7A024-63B5-4515-A887-1DD865293AC0Q37649231-0F4149E5-CAAF-41F9-B77E-FA3747FE700FQ38103187-B965A21A-F822-412C-9202-288FD6307F25Q38121995-8663DB68-C7FA-4220-8226-78E84E5075E9Q38281374-9619404E-FEBD-47D7-B8FC-4577CC707614Q38471824-D3391CBE-543C-4471-9F8B-1D6B5683F784Q38840383-ADB8C1A6-B086-4002-8C3B-A877CD841085Q40259346-FFE15D36-B4BB-4BEB-A5BF-D595DFF72AD3Q41657305-35168540-45F6-4E21-B80B-CE695D77EB9AQ46340306-F62DC4F8-3201-41E1-B1CE-F92D668EBC5BQ49247828-4F6C48D3-D545-41CE-8162-73CE00574713Q51721747-8174EBB5-A4BE-4C32-B1E5-DA556289D448
P2860
Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Divergent genomic and epigenom ...... hways during tumor development
@ast
Divergent genomic and epigenom ...... hways during tumor development
@en
Divergent genomic and epigenom ...... hways during tumor development
@nl
type
label
Divergent genomic and epigenom ...... hways during tumor development
@ast
Divergent genomic and epigenom ...... hways during tumor development
@en
Divergent genomic and epigenom ...... hways during tumor development
@nl
prefLabel
Divergent genomic and epigenom ...... hways during tumor development
@ast
Divergent genomic and epigenom ...... hways during tumor development
@en
Divergent genomic and epigenom ...... hways during tumor development
@nl
P2093
P2860
P50
P3181
P1433
P1476
Divergent genomic and epigenom ...... hways during tumor development
@en
P2093
Adi F Gazdar
Bradley P Coe
Carmen Behrens
Ian M Wilson
John D Minna
John English
Kelsie L Thu
Larissa A Pikor
Luisa M Solis
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0037775
P407
P577
2012-01-01T00:00:00Z